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Introduction: The dynamics of prostate speciﬁc antigen (PSA) in patients who have prostate cancer and
receive radiotherapy is a very interesting but complicated topic. We tried to plot the sequential changes
of PSA with and without hormone therapy and tried to ﬁnd out the predictors for the high-risk patients
for prostate cancer recurrence.
Methods: We reviewed the medical records of 164 prostate cancer patients who underwent intensity-
modulated radiation therapy (IMRT) as the primary treatment. We recorded the patients’ age, initial
PSA, cancer grading at diagnostic biopsies (Gleason’s score), clinical stage, the IMRT dosage, neoadjuvant,
concomitant, and prolonged hormone therapy, follow-up PSA levels, biochemical progression, and
distant metastasis.
Results: Of the 84 patients undergoing radiotherapy for prostate cancer with complete data for analysis,
the biochemical failure-free survival (BFFS) rate was 88.09%. The patients with an initial PSA of less than
10 ng/mL had the best BFFS. Of the patients receiving neoadjuvant hormone therapy (NHT), serum PSA
levels were signiﬁcantly higher in those with biochemical failure than those without biochemical failure
in the 3 months after radiation therapy. As for the patients free of biochemical failure, the mean PSA fell
below 1 ng/mL immediately after IMRT for the NHT(þ) group and at 9 months after IMRT for the NHT(e)
group.
Conclusion: For the patients with localized prostate cancer who underwent IMRT, initial PSA could
predict clinical stage, 1-year BFFS, and 2-year BFFS. The follow-up PSA, as early as 3 months, was of
clinical predictive value.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
The combination of prostate speciﬁc antigen (PSA) and digital
rectal examination has been proposed as less costly and more
speciﬁc with equal sensitivity to early prostate cancer detection.1
PSA, a member of the kallikrein-type serine protease family,
abundant both in benign and malignant prostate tissue, was
introduced as an organ-speciﬁc serum biomarker for prostate
cancer in the 1980s.2 Although PSA was developed as a screening
tool, it is also an ideal surrogate marker for the follow-up ofNational Taiwan University
an.
ng).
ciation. Published by Elsevier Taiwtreatment effects and evaluation of prognoses. Freedland et al3
documented that PSA levels at diagnosis could be effective in pre-
dicting prostate cancer prognosis after radical prostatectomy. We
were inspired by their article to study whether the predictive value
of PSA also exists in biochemical failure (BF) and distant metastasis
(DM) of the patients undergoing external radiation therapy for
prostate cancer.
The dynamics of PSA after radiation therapy is a very interesting
and complicated topic because the applications of neoadjuvant,
concurrent, and prolonged hormone therapy could all affect serum
PSA levels.4 In this study, we made efforts to plot the sequential
changes of PSAwith andwithout hormone therapy and tried to ﬁnd
early cutoff points for the high-risk patients to receive salvage
intervention.an LLC. Open access under CC BY-NC-ND license.
Table 1
The patients’ characteristics with age, initial PSA, Gleason sum, T classiﬁcation,
hormone therapy, biochemical failure, and distant metastasis.
Subgroup No. of patients (%)
Total 84
Age (y) <65 14 (16.7)
65 70 (83.3)
iPSA (ng/mL) <10 27 (32.1)
10e19.9 26 (31.0)
20e99.9 27 (32.1)
100 4 (4.8)
Gleason sum 2e4 4 (4.8)
5e6 19 (22.6)
7e10 61 (72.0)
T Classiﬁcation 1e2 45 (53.6)
3 39 (46.4)
Neoadjuvant hormone therapy With 66 (78.6)
Without 18 (21.4)
Biochemical failure 1-y 9 (10.7)
2-y 20 (23.8)
Distant metastasis 1-y 1 (1.2)
2-y 4 (4.8)
iPSA ¼ initial serum PSA concentration.
Table 2
Clinical and pathological features in patients receiving external radiation therapy for
prostate cancer stratiﬁed by initial PSA.
Initial PSA (ng/mL) p
All patients <10 10e19.9 20e99.9 100
Patients (N) 84 27 26 27 4
Age (y) 72.2 70.2 74.6 72.1 70.7 0.24
Gleason sum
2e4 4 (4.8) 2 (7.4) 1 (3.8) 1 (3.7) 0 (0) 0.26
5e6 19 (22.6) 9 (33.3) 6 (23.1) 3 (11.1) 1 (25.0)
7 48 (57.1) 15 (55.6) 16 (61.5) 23 (55.6) 3 (50)
8e10 13(15.5) 1(3.7) 3(11.5) 8(29.6) 1(25)
Clinical stage, T
T1eT2 45 (53.6) 24 (88.9) 15 (57.7) 6 (22.2) 0 (0) <0.01
T3 39 (46.4) 3 (11.1) 11 (42.3) 21 (77.8) 4 (100.0)
Biochemical failure
1-y 9 (10.7) 1 (3.7) 3 (11.5) 3 (11.1) 2 (50.0) 0.049
2-y 20 (23.8) 3 (11.1) 6 (23.1) 8 (29.6) 3 (75.0) 0.034
Distant metastasis
1-y 1 (1.2) 0 (0.0) 0 (0.0) 1 (3.7) 0 (0.0) 0.545
2-y 4 (4.8) 1 (3.7) 0 1 (3.7) 2 (50) <0.01
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After obtaining Institutional Review Board approval, we
searched for the keyword “prostate cancer” in the National Taiwan
University Hospital Cancer Registration Database between January
2002 and December 2006. Of the 1076 patients retrieved from the
database, there were 164 patients receiving external radiation
therapy with deﬁnitive intensity-modulated radiotherapy (IMRT)
as the primary treatment with or without neoadjuvant hormone
therapy. After excluding the patients with metastasis at diagnosis,
incomplete PSA data, or loss of follow-up, 84 patients were
included in the study for further analysis. IMRT was delivered in
conjunction with image-guided radiation therapy.5 As described in
the article by Wang et al,5 all patients were treated with 10-MV
photon beams from a Siemens Primus or Elekta Synergy linear
accelerator. The margins for planning target volume were 0.6 cm in
the posterior direction and 1.0 cm in other directions. During each
treatment, patients were placed in a prone position in a vacuum
bag for torso immobilization, and with an endorectal balloon
inserted and then inﬂated with 60 mL of air for prostate immobi-
lization and rectum sparing. The PSA level was followed every 3
months after radiotherapy.
We reviewed the data of the patients, including the patients’
age, initial serum PSA concentration, cancer grading at diagnostic
biopsies, clinical stage (deﬁned by digital rectal examination), the
IMRT dosage, neoadjuvant, concomitant, and prolong hormone
therapy, and follow-up PSA levels. A biochemical progression was
deﬁned as a single PSA elevation of 2 ng/mL or three persistent PSA
elevations.6 Metastasis was deﬁned with positive ﬁndings from
whole body bone scan, computed tomography, or chest X-ray.
Preradiotherapy serum PSA, postradiotherapy serum PSA (PSA0),
PSA nadir, and postradiotherapy serum PSA at 3 months, 6 months,
9 months,12months,18months, and 24months (PSA3, PSA6, PSA9,
PSA12, PSA18, and PSA24) were recorded. Neoadjuvant hormonal
androgen deprivation therapy (NHT) started 1e3 months prior to
the initiation of IMRT. The regimens included Cyproterone acetate
(Androcur), Bicalutamide (Casodex), Flutamide (Fugerel), Leupro-
lide acetate (Leuplin), or Triptorelin (Decapeptyl CR). NHT was
given with the intention of controlling the disease extent,
decreasing the prostate volume, and potentially facilitating the
delivery of escalated radiation dose.
Chi-square test and Student t test were used for statistical
analysis.3. Results
Of the 84 patients enrolled for data analysis, the median dose to
the clinical target volume was 78.3 Gy (range, 70.00e81.51 Gy) in
39 daily fractions of 1.79e2.09 Gy over 8 weeks. The patients’
characteristics, including patients’ age, initial serum PSA, percent-
age of free PSA, Gleason sum, and clinical stage are summarized in
Table 1.
The follow-up duration ranged from 2.03 years to 6.12 years
with a mean of 3.65 years. The 2-year overall survival rate was
100%. However, one patient died of cardiovascular disease 2.6 years
after IMRT, and two patients died of prostate cancer 2.3 years and
3.2 years after IMRT, respectively. The 2-year biochemical failure-
free survival (BFFS) rate was 88.09%. The 2-year distant
metastasis-free survival (DMFS) rate was 95.2%. One patient was
noted to have bone metastasis 2.7 years after radiation therapy.
After subgrouping, the patients with their initial serum PSA at
diagnosis, clinical stage, pathological features, BFFS, and DMFS rate
are listed in Table 2. Initial serum PSA has a statistically signiﬁcant
predictive value in terms of clinical stage, 1-year BFFS, 2-year BFFS,
and 2-year DMFS.
Serum PSA levels at diagnosis, prior to radiation therapy, and at
0months, 3months, 6months, 9months,12months,18months, and
24months after IMRTare listed according to the presence or absence
of BF and DM in Table 3. Of the patients receiving neoadjuvant hor-
mone therapy, serumPSA levelswere signiﬁcantlyhigher in theBF(þ)
group than in theBF(e) group3monthsafter radiation therapy.Of the
patients without neoadjuvant hormone therapy, serum PSA levels
were always higher in the BF(þ) group. More speciﬁcally, the 3-
month PSA was 1.46 ng/mL and 0.46 ng/mL (p ¼ 0.027) for NHT(þ)
BF(þ) andNHT(þ)BF(e), respectively. The3-monthPSAwas26.35ng/
mL and 1.48 ng/mL for NHT(e)BF(þ) and NHT(e)BF(e), respectively.
As for the patients free of BF, the mean PSA fell below 1 ng/mL
immediately after radiation therapy for the patients with neo-
adjuvant hormone therapy, and themean PSA fell below 1 ng/mL at 9
months after radiation therapy for the patient without NHT.
4. Discussion
According to the guidelines of prostate cancer treatment, pa-
tients with localized prostate cancer should be informed of the
treatment options, including active surveillance, radiotherapy
(external beam and interstitial radiation therapy), and radical
prostatectomy.7 External beam radiation therapy is the treatment
choice for most men with early-stage prostate cancer. Unlike
Table 3
Serum PSA levels after radiation therapy at 3, 6, 9, 12, 18, and 24 months with/without neoadjuvant hormone therapy (NHT).
No. Initial PSA Pre-RT PSA PSA0 PSA3 PSA6 PSA9 PSA12 PSA18 PSA24
NHT(þ) 66 27.3  25.7 2.9  4.5 1.22 0.72 0.89 0.67 0.62 1.97 2.98
BF(þ) 18 35.1  33.5 4.4  6.4 1.89 1.46 1.99 1.57 1.52 6.9 10.53
BF(e) 48 24.3  21.8 2.3  3.5 0.95 0.46 0.50 0.33 0.28 0.18 0.15
p 0.131 0.092 0.175 0.027 0.031 0.001 0.008 0.016 0.012
DM(þ) 3 55.4  58.6 7.5  7.4 2.91 2.21 5.02 1.96 5.11 38.36 49.71
DM(e) 63 25.9  23.2 4.3  2.6 2.50 1.57 2.22 1.04 0.57 1.92 0.79
p 0.068 0.438 0.105 0.022 <0.01 <0.01 <0.01 <0.01 <0.01
NHT(e) 18 16.5  28.2 11.4  16.9 9.44 4.24 2.17 1.44 1.04 0.78 0.65
BF(þ) 2 76.7  54.0 40.7  52.7 63.40 26.35 11.17 7.17 4.43 2.79 4.43
BF(e) 16 9.5  6.8 7.8  3.3 2.70 1.48 1.04 0.72 0.62 0.53 0.43
p <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
DM(þ) 1 126.5 78.0 125.5 52.52 22.29 14.06 8.25 5.39 7.53
DM(e) 17 10.0  7.0 7.5  3.4 2.55 1.41 0.99 0.70 0.62 0.51 0.42
p <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
BF ¼ biochemical failure; DM ¼ distant metastasis; PSA0 ¼ postradiotherapy serum PSA.
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therapy has few contraindications, regardless of age, health status,
or prostate size.8 IMRT was introduced into our institution in 2003.
The modern radiation modality, an advancement from 3D
conformal treatment, is believed to reduce rectal injury in com-
parison with conventional radiotherapy and to enhance the con-
formality of the dose distribution around the tumor target.9
Comparing the patients’ characteristics of our institution with the
data from New York, the patients receiving IMRT in Taiwan tend to
have higher proportions of PSA greater than 20 (36.9% vs. 8%) and
stage T3 cancer (46.4% vs. 6%). This could be attributable to the
prostate cancer screening program or the patients’ attitudes toward
radiotherapy. We need further epidemiological studies to clarify
the condition.
PSA is widely used as a detecting, diagnosing, prognosis deter-
mining, and clinical decision making biomarker for prostate cancer.
Since its discovery in 1979, PSA has not only been used as a
screening tool, but also as a predictor of prostate tumor volume,
stage, and prognosis.10 Freedland et al3 have proposed that the
higher preoperative PSA levels of the patients receiving radical
prostatectomy could predict extracapsular extension, positive sur-
gical margins, seminal vesicle invasion, pathological stage, and
biochemical progression. After subgrouping initial PSA at diagnosis,
we also noted that the clinical stage, BF, and DM rate increased
signiﬁcantly with PSA elevation.
There are various deﬁnitions of BF following radiotherapy,
which might not completely correlate with clinical results.6 We
adopted the same criteria used by Zelefsky et al.9 A PSA relapse was
deﬁned according to the American Society for Radiation Oncology
(ASTRO) consensus deﬁnition (3 successive PSA increases after a
posttreatment nadir was achieved)11 and according to the Houston
deﬁnition (absolute nadir plus 2 ng/mL dated at the call).12 They
reviewed 561 patients with localized prostate cancer treated by
IMRT. The 8-year PSA relapse-free survival rates for favorable, in-
termediate, and unfavorable groups were 85%, 76%, and 72%,
respectively. DM developed in 3%. T stage greater than T2c and
pretreatment PSA greater than 10 ng/mL had signiﬁcantly higher
risk for PSA relapse. Overall, 2-year BFFS and 2-year DMFS of the
patients who underwent IMRT because of localized prostate cancer
were 76.2% and 95.2%, respectively, in our study. Long-term prog-
nosis still needs further evaluation. Two-year BFFS, and 1-year and
2-year DMFS were all signiﬁcantly decreased with higher pre-
treatment PSA.
PSA nadir could predict biochemical recurrence after external
radiation beam therapy for prostate cancer. A PSA nadir of 0.5 ng/
mL or less represents an early endpoint strongly predictive of a
favorable outcome following radiation therapy.13It is time consuming to identify the absolute PSA nadir. Thus,
Alcantara et al came upwith an idea regarding the nadir PSAwithin
12 months after radiation therapy (nPSA12), in which they used
2 ng/mL as a cutoff point. The 5-year BF rates for the patients with
an nPSA12 >2 and <2 ng/mL were 36% and 26%, respectively
(p¼ 0.0015). An nPSA12>2 ng/mLwas associated with a 4-fold risk
of DMF.14
We meticulously examined the 3 months, 6 months, 9 months,
12 months, 18 months, and 24 months PSA levels after radiation
therapy and subgrouped the patients into patients with and
without neoadjuvant hormone therapy. The NHT(þ) and NHT(e)
groups were both divided according to the presence of BF or DM. As
for the NHT(þ) group, the PSA levels began to present statistically
signiﬁcant difference between the BF(þ) and BF(e) groups 3
months after radiotherapy. For the NHT(e) group, the PSA levels
had a signiﬁcant difference between the BF(þ) and BF(e) groups
with the pretreatment initial PSA and all further PSA levels. The
same trend was also noted in the analysis of DM.
Notably, in the NHT(e) group, BF(þ) and DM(þ) patients had
their PSA0 > PreRT PSA. One possible explanation is that micro-
metastasis, which could not be detected by imaging studies, could
have happened prior to the initiation of radiotherapy, thus resulting
in PSA0 > PreRT PSA. Nonetheless, PSA0 > PreRT PSA could be a
predictor for BF(þ) or DM(þ) in NHT(e) patients. Another distinct
ﬁnding is that the initial serum PSA concentration was always
higher than PreRT PSA in the NHT(e) group. Because of the small
sample size, the PSAvalue could be largely affected by some speciﬁc
individuals who might have experienced concurrent infection,
laboratory error, or even alternative treatment beyond our moni-
toring scope. A larger study is needed to clarify this situation.
The mean PSA of NHT(e)BF(þ) and NHT(e)BF(e) 12 months
after radiotherapy were 4.43 ng/mL and 0.62 ng/mL, respectively.
The ﬁnding is consistent with the cutoff point 2 ng/mL set by
Alcantara et al.15 However, the mean PSA of NHT(þ)BF(þ) and
NHT(þ)BF(e) 12 months after radiotherapy was 1.52 ng/mL and
0.28 ng/mL, respectively. The ﬁnding suggested that a lower cutoff
value of nPSA 12 could be proposed for patients with neoadjuvant
hormone therapy. We did not compare the effects of treatment
with NHT and without NHT because the mean PSA of the two
groups are far too different in the ﬁrst place. The topic might be
investigated in a further multicentered database.
The major limitations of our study are the limited case
numbers and the variability of androgen deprivation therapy and
follow-up methods between each physician. There is a relatively
low incidence of prostate cancer in Taiwan, and the patients’
characteristics are not identical to those of the patients in Western
countries.16 Although the case numbers in this study are limited,
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male with prostate cancer undergoing IMRT with or without NHT,
and they also showed the PSA dynamic changes after IMRT. The
association of pretreatment PSA and BF after radiotherapy is
documented in previous studies and is well accepted.17,18 The use
of PSA dynamics as a marker needs to take into account its
dependence on pretreatment variables. Further prospective
studies could be conducted to obtain an appropriate follow-up PSA
cutoff point to treat the patients with higher risk of disease pro-
gression earlier.
In conclusion, for patients with localized prostate cancer un-
dergoing IMRT, pretreatment initial PSA could predict clinical stage,
1-year BFFS, 2-year BFFS, and 2-year DMFS. The PSA levels at 3
months after radiotherapy was signiﬁcantly different between the
NHT(þ)BF(þ) and NHT(þ)BF(e) groups, which is of predictive value
for further salvage intervention.
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